Literature DB >> 2454993

Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera.

H H Guldner1, H J Netter, C Szostecki, H J Lakomek, H Will.   

Abstract

Several cDNA fragments encoding parts of the (U1)RNP specific 68-kDa autoantigen were expressed in Escherichia coli and the fusion proteins were used as substrate for localization of the autoreactive epitopes. We have identified a region of approximately 30 amino acids reacting with more than 90% (16 of 17) of all human anti-p68 sera tested, regions which carry only a few and a region with no autoepitopes. Comparative analysis of epitopes recognized on partially degraded fusion proteins indicated that the anti-p68 autoimmune response is polyclonal. It involves generation of antibodies to several epitopes including one in a region with retroviral gag protein homology speculated to play a role in the initiation of the autoimmune response. Each of the 17 sera tested contained a different set of autoantibody specificities. These data are not consistent with random mutation as a sole mechanism of anti-p68 autoantibody induction and argue for an Ag-driven autoimmune response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454993

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Analysis of the autoimmune epitopes on human testicular NASP using recombinant and synthetic peptides.

Authors:  I N Batova; R T Richardson; E E Widgren; M G O'Rand
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Mapping of epitopes recognized by anti-(U1)RNP autoantibodies.

Authors:  H H Guldner
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 3.  Antinuclear antibody determination methods.

Authors:  D G Williams; P J Charles; M Field; S M Chua; R N Maini
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  Analysis of autoantibodies to recombinant La (SS-B) peptides in systemic lupus erythematosus and primary Sjogren's syndrome.

Authors:  P Bini; J L Chu; C Okolo; K Elkon
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

Review 5.  cDNA cloning of small nuclear and cytoplasmic RNA-associated proteins.

Authors:  A van Dam; I Winkel; R Smeenk; T Cuypers
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

6.  HLA class II restriction of autoantibody production in patients with systemic lupus erythematosus.

Authors:  H A Stephens; N J McHugh; P J Maddison; D A Isenberg; K I Welsh; G S Panayi
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

7.  Immunoreactivity between a monoclonal lupus autoantibody and the arginine/aspartic acid repeats within the U1-snRNP 70K autoantigen is conformationally restricted.

Authors:  S Pelsue; P F Agris
Journal:  J Protein Chem       Date:  1994-05

8.  A common autoepitope near the carboxyl terminus of the 60-kD Ro ribonucleoprotein: sequence similarity with a viral protein.

Authors:  R H Scofield; W D Dickey; K W Jackson; J A James; J B Harley
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

9.  Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa.

Authors:  J C Lapiere; D T Woodley; M G Parente; T Iwasaki; K C Wynn; A M Christiano; J Uitto
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

10.  Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies.

Authors:  Claudia Azucena Palafox Sánchez; Minoru Satoh; Edward Kl Chan; Wendy C Carcamo; José Francisco Muñoz Valle; Gerardo Orozco Barocio; Edith Oregon Romero; Rosa Elena Navarro Hernández; Mario Salazar Páramo; Antonio Cabral Castañeda; Mónica Vázquez Del Mercado
Journal:  Arthritis Res Ther       Date:  2009-02-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.